Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Healthy Clinical Trial

Official title:

International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.А., Italy) After Single Subcutaneous Administration to Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01766024
• Other study ID #: BCD-033-1
• Status: Completed
• Phase: Phase 1
• First received: January 10, 2013
• Last updated: February 2, 2015
• Start date: February 2013
• Est. completion date: June 2013

Study information

• Verified date: February 2015
• Source: Biocad
• Contact: n/a
• Is FDA regulated: No
• Health authority: Russian Federation: Ministry of Health of the Russian Federation
• Study type: Interventional

Clinical Trial Summary

This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and tolerability of BCD-033 (interferon beta-1a manufactured by CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.A.., Italy) in healthy volunteers. The purpose of the study is to demonstrate the non-inferiority of pharmacokinetics, pharmacodynamics and tolerability parameters after single subcutaneous injection. Each dtug will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.

Description:

Each dtug (BCD-033 and Rebif) will be administered to each volunteer at a dose of 44 µg as a single subcutaneous injection with an interval of at least 14 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Written informed consent;

• Male gender;

• Age 18 - 45 years inclusive;

• Body mass index (BMI) (18,5 - 24,99 kg/m2);

• Healthy condition proven by the volunteer's history, global assessment and laboratory analysis results:

• Absence in past medical history and at screening of clinically significant dysfunctions of circulatory, respiratory, nervous, hematopoietic, endocrine and digestive systems, liver and kidneys;

• Haematology and biochemistry tests, urinalysis and thyroid hormone analysis results are within normal limits according to standards of the study site. Screening laboratory analyses should be performed not more than 14 days before volunteer's inclusion in the study;

• Hemodynamic parameters are within normal limits: systolic blood pressure - from 100 to 139 mmHg, diastolic blood pressure - from 60 to 90 mmHg, heart rate - from 50 to 90 bpm;

• Absence of history of chronic infection (tuberculosis) and chronic inflammation;

• Absence of HIV, hepatitis B and C virus, syphilis;

• Absence of acute infections within 4 weeks before inclusion in the study;

• Absence of psychiatric disorders and other conditions that can interfere with volunteer's ability to follow the study protocol, including depression;

• Well-being (in volunteer's opinion) within 30 days before participation in the study;

• Absence of history of systematic alcohol and drug abuse;

• Ability of the volunteer, in investigator's opinion, to follow the study protocol procedures and requirements;

• Willingness of volunteers and their sexual partners of childbearing potential to use reliable contraception methods starting from 2 weeks before inclusion into the study and until 4 weeks after receiving the last dose of the investigational products. This criterion is not applicable to patients who underwent surgical sterilization. Reliable contraceptive measures include one barrier method in combination with one of the following methods: spermicides, intrauterine device or oral contraceptives used by participant's partner;

• Consent to avoid alcohol intake within 24 hours before and 8 days after each administration of the test or reference drugs;

• Consent to avoid grapefruit juice (or other products containing grapefruit) intake within 72 hours before and 8 days after each administration of the study or reference drugs.

Exclusion Criteria:

• Previous use of IFN-ß1-containing medications at any time before inclusion;

• History of serious allergic reactions (anaphylaxis or multiple allergy);

• Known allergy or intolerance to interferons or any other components of study or reference drugs;

• Major surgery within 30 days before screening;

• Impossibility to install venous catheter for blood sampling (e.g. because of skin disorders at the sites of venipuncture);

• Diseases or other conditions that can interfere with the investigational drugs pharmacokinetics (e.g. chronic liver, kidney, blood, circulatory system, lung or neuroendocrine diseases, including diabetes mellitus and others);

• History of epileptic seizures;

• Regular oral or parenteral use of any medications including over-the-counter drugs, vitamins and nutritional additives within less than 2 weeks before inclusion in the study;

• Intake of medications, including over-the-counter drugs and biologically active additives that can influence hemodynamics, liver function etc. (barbiturates, omeprazole, cimetidine etc.) within less than 30 days before inclusion in the study;

• Intake of medications that influence immune status (cytokines and their inductors, glucocorticoids etc.) within less than 30 days before participation in the study;

• Smoking more than 10 cigarettes per day;

• Subjects who consume more than 10 units of alcohol per week or who have history of alcohol abuse or evidence of drug/chemical abuse (one unit of alcohol equals ½ l [500 ml] of beer, one glass [200 ml] of wine or l shot glass [50 ml] of spirits);

• Donation of 450 ml and more of blood or plasma within 2 months before inclusion in the study;

• Participation in other clinical studies within less than 1 month before inclusion in the study or simultaneous participation in another clinical study;

• Previous participation in this study

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Interferon beta-1a
Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.

Locations

Country	Name	City	State
Russian Federation	City Mariin Hospital	St. Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Biocad

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under Concentration-time Curve (AUC) of Interferon (IFN) Beta-1a From the Moment of Drug Administration Until 48 Hours and to Infinity(AUC(0-48) and AUC(0-8) Respectively)	Primary outcome measure for pharmacokinetics analysis	up to 48 h	No
Primary	Cmax of Interferon Beta-1a	Primary outcome measure for pharmacokinetics analysis	up to 48 h	No
Primary	AUC(0-168) and AUC(0-8) of Neopterin and MxA Protein	Primary outcome measure for pharmacodynamics analysis	up to 168 h	No
Secondary	?max of Interferon Beta-1a	Secondary outcome measure for pharmacokinetics analysis	up to 48 h	No
Secondary	?½ of Interferon Beta-1a	Secondary outcome measure for pharmacokinetics analysis	up to 48 h	No
Secondary	?el of Interferon Beta-1a	Secondary outcome measure for pharmacokinetics analysis	up to 48 h	No
Secondary	Cl of Interferon Beta-1a	Secondary outcome measure for pharmacokinetics analysis	up to 48 h	No
Secondary	Cmax of Neopterin and MxA Protein	Secondary outcome measure for pharmacodynamics analysis	up to 168 h	No
Secondary	Tmax of Neopterin and MxA Protein	Secondary outcome measure for pharmacodynamics analysis	up to 168 h	No
Secondary	Adverse Event (AE) and Serious Adverse Event (SAE) Incidence	Secondary outcome measure for safety assessment	up to Day 43	Yes
Secondary	AE of Garde 3-4 Incidence	Secondary outcome measure for safety assessment	up to Day 43	Yes
Secondary	Local Reaction Incidence	Secondary outcome measure for tolerability assessment	up to Day 43	Yes
Secondary	Study Withdrawal Rate Due to AE	Secondary outcome measure for safety assessment	up to Day 43	Yes

External Links

•   Link